Year: 2021

TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today the release of its unaudited interim condensed consolidated financial statements and accompanying management’s discussion and analysis (MD&A) for the three and nine months ended September 30, 2021. All financial figures contained herein are expressed in U.S. dollars (“USD”) unless otherwise noted. Third Quarter and First Nine Months 2021 HighlightsGran Colombia is continuing to implement its strategy to grow through diversification while returning value to its shareholders through its monthly dividend program.   On June 4, 2021, Gran Colombia acquired all of the shares of Gold X Mining Corp (“Gold X”) it did not already own and then closed a $300 million offering on August 9, 2021 of 6.875% Senior Unsecured Notes due...

Q3 2021 Key Highlightsrevenues of $103.0 million adjusted EBITDA of $41.2 million net income of $15.7 million free cash flow of $2.3 million9M 2021 Key Highlightsrevenues of $296.5 million adjusted EBITDA of $95.5 million net income of $27.2 million free cash flow of $42.4 millionRevised FY 2021 Guidanceincreased adjusted EBITDA guidance to $120-130 million increased maintenance capex guidance to $23-26 million tightened growth capex guidance to $13-15 million increased free cash flow guidance to $60-70 millionCEO Commentary “We delivered record operational and financial performance during Q3 2021, resulting in a year-to-date 2021 adjusted EBITDA at Conda of $107.7 million and $95.5 million on a consolidated basis,” said G. David Delaney, CEO of Itafos. “We are raising our full-year guidance for 2021 to reflect the continued...

RIO DE JANEIRO, Brazil, Nov. 11, 2021 (GLOBE NEWSWIRE) — Vinci Partners Investments Ltd. (NASDAQ: VINP) (“Vinci Partners”, “we”, “us” or “our”), the controlling company of a leading alternative investment platform in Brazil, announced today that “Vinci Impacto e Retorno IV”, or “VIR IV” (“the Fund”), the Impact family of funds managed by Vinci Partners’ Private Equity strategy, closed an acquisition equivalent to a 34.0% stake in Verdfrut (“the Company”), a Brazilian SME Fruits & Vegetables (F&V) retailer and B2B Distribution operation (DC). VIR IV has a unique strategy in Brazil, with a dual mandate to generate favorable market returns as well as impact, through the acquisition of minority holdings in small-and-medium sized Brazilian enterprises, that exhibit growth potential and clear measurable environmental, social...

MONTRÉAL, Québec, Nov. 11, 2021 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the fiscal year ended July 31, 2021. “IBEX had another very good year, with EBITDA reaching a record level”, said Mr. Baehr, IBEX President & CEO. “The strong financial performance resulted from near-record revenues and a reduction in expenses, due mainly to the closure of the Iowa production facility. The increase in revenues was driven by strong sales of heparinase-based products.” He further stated: “We were particularly pleased by the strong fourth quarter sales which may be an indicator of a return to more normal purchasing patterns by our customers in the hemostasis diagnostics market segment.” Note: All figures are in Canadian dollars unless otherwise stated....

+2% Increase in Monthly Distributions Commencing in 2022 +8% NAV Growth since the Beginning of 2021 $28 Million of YTD Capital Recycling $124 Million in YTD Acquisitions TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”), (TSXV: FCD.UN) is pleased to report its financial results for the period ended September 30, 2021, a 2% distribution increase (48.6% cumulative distribution increases in nine years or since inception) and 8% NAV growth since the beginning of 2021: TENANT DIVERSIFICATION The portfolio is well diversified by tenant profile with no tenant currently accounting for more than 11.7% of total net rent. Further, the top 10 tenants are comprised of large national tenants and account for 30.7% of total net rent. PROPERTY PORTFOLIO HIGHLIGHTS The portfolio consists of 62 commercial...

VANCOUVER, British Columbia, Nov. 11, 2021 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) announced that it has granted options to acquire a total of 13,000,000 common shares of the Corporation to officers, directors, and consultants, pursuant to the Corporation’s Stock Option Plan, at the exercise price of $0.12 per share for a period of five years. The options are granted pursuant to the Corporation’s Stock Option Plan, under which a maximum of ten percent (10%) of the issued and outstanding common shares are reserved for issuance.  About Fancamp Exploration Ltd. (TSX-V: FNC) Fancamp is a growing Canadian mineral exploration corporation dedicated to its value-added strategy of advancing mineral properties through exploration and development. The Corporation owns...

Reports third quarter 2021 total revenue of $6.9 million and commercial revenue of $6.3 million Reaffirms full-year 2021 commercial revenue outlook of at least $24.0 million, representing at least 70% year-over-year growth LOWELL, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2021. Financial Highlights and Business UpdateRecorded commercial revenue of $6.3 million for the third quarter of 2021, representing 27% year-over-year growth. Generated recurring commercial revenue of $2.2 million, representing 154% year-over-year...

LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator Masatsune Ogura, M.D., Ph.D., Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, is presenting results and findings of a study that investigated the mechanism by which MN-001 (tipelukast) alters triglyceride (TG) metabolism in hepatocytes at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) to be held online from November 12th to 15th. In this study, HepG2 cells derived from human hepatocellular carcinoma samples were incubated for 48 hours...

Brings Extensive Experience as Former Federal CIO for U.S. Government as well as Fortune 100 Companies PLANO, Texas, Nov. 11, 2021 (GLOBE NEWSWIRE) — INTRUSION (Nasdaq: INTZ), a leader in cyberattack prevention solutions including zero-days, today appointed Tony Scott as its new President and CEO, who will assume the role on Monday, November 15, 2021. Scott brings to INTRUSION many years of executive leadership and cybersecurity experience, including serving as Federal CIO for the U.S. government, CIO for multi-billion corporations such as VMware, Microsoft and The Walt Disney Company, as well as a private consultant helping organizations implement effective world class solutions for cybersecurity, IT governance and crisis management. Prior to his appointment, Scott had been serving as the founder and CEO of the TonyScottGroup,...

Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain blood cancers LCD supports the expansion of coverage for additional clonoSEQ indications, providing a clear pathway for Non-Hodgkin’s Lymphoma (NHL) and other lymphoid cancersSEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that Palmetto GBA’s Molecular Diagnostics Program (MolDX) has finalized a local coverage determination (LCD) which supports the Medicare coverage for clonoSEQ® to detect and monitor minimal residual...